Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy—A Review

Król, Katarzyna; Mazur, Artur; Stachyra-Strawa, Paulina; Grzybowska‐Szatkowska, Ludmiła

doi:10.3390/ijms24065858

Cited by 8 publications

(5 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For advanced NSCLC, highly effective targeted therapies have been approved in many places for patients with EGFR-activating mutations, ALK fusions and ROS1 fusions ( 53 , 54 ). The development of novel targeted therapies for patients with advanced NSCLC with specific genetic alterations (driver mutations) has greatly improved response rates and survival compared to previously available treatments ( 6 , 55 ). However, the accessibility of targeted therapies for lung cancer depends on the accurate identification of patient biomarkers through molecular testing ( 56 ).…”

Section: Discussionmentioning

confidence: 99%

Three-year follow-up study reveals improved survival rate in NSCLC patients underwent guideline-concordant diagnosis and treatment

Mu,

Yang,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

BackgroundNo studies in China have assessed the guideline-concordance level of the first-course of non-small cell lung cancer (NSCLC) diagnosis and treatment and its relationship with survival. This study comprehensively assesses the current status of guideline-concordant diagnosis (GCD) and guideline-concordant treatment (GCT) of NSCLC in China and explores its impact on survival.MethodsFirst course diagnosis and treatment data for NSCLC patients in Liaoning, China in 2017 and 2018 (n=1828) were used and classified by whether they underwent GCD and GCT according to Chinese Society of Clinical Oncology (CSCO) guidelines. Pearson’s chi-squared test was used to determine unadjusted associations between categorical variables of interest. Logistic models were constructed to identify variables associated with GCD and GCT. Kaplan–Meier analysis and log-rank tests were used to estimate and compare 3-year survival rates. Multivariate Cox proportional risk models were constructed to assess the risk of cancer mortality associated with guideline-concordant diagnosis and treatment.ResultsOf the 1828 patients we studied, 48.1% underwent GCD, and 70.1% underwent GCT. The proportions of patients who underwent both GCD and GCT, GCD alone, GCT alone and neither GCD nor GCT were 36.7%, 11.4%, 33.5% and 18.4%, respectively. Patients in advanced stage and non-oncology hospitals were significantly less likely to undergo GCD and GCT. Compared with those who underwent neither GCD nor GCT, patients who underwent both GCD and GCT, GCD alone and GCT alone had 35.2%, 26.7% and 35.7% higher 3-year survival rates; the adjusted lung cancer mortality risk significantly decreased by 29% (adjusted hazard ratio[aHR], 0.71; 95% CI, 0.53–0.95), 29% (aHR, 0.71; 95% CI, 0.50–1.00) and 32% (aHR, 0.68; 95% CI, 0.51–0.90).ConclusionThe 3-year risk of death is expected to be reduced by 29% if patients with NSCLC undergo both GCD and GCT. There is a need to establish an oncology diagnosis and treatment data management platform in China to monitor, evaluate, and promote the use of clinical practice guidelines in healthcare settings.

show abstract

Section: Discussionmentioning

confidence: 99%

Three-year follow-up study reveals improved survival rate in NSCLC patients underwent guideline-concordant diagnosis and treatment

Mu,

Yang,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The combined application of Rhapontin and Ceritinib, while not achieving the zenith of efficacy exhibited by certain established combination therapies, merits profound scrutiny ( Krol et al, 2023 ). The nuanced response could stem from intricate intracellular interactions, wherein Rhapontin’s engagement with alternative molecular targets competes with its interaction with FGFR3 ( Ho et al, 2014 ; Cascetta et al, 2022 ).…”

Section: Discussionmentioning

confidence: 99%

Active and machine learning-enhanced discovery of new FGFR3 inhibitor, Rhapontin, through virtual screening of receptor structures and anti-cancer activity assessment

Zeng,

Hu,

Huang

et al. 2024

Front. Mol. Biosci.

View full text Add to dashboard Cite

Introduction: This study bridges traditional remedies and modern pharmacology by exploring the synergy between natural compounds and Ceritinib in treating Non-Small Cell Lung Cancer (NSCLC), aiming to enhance efficacy and reduce toxicities.Methods: Using a combined approach of computational analysis, machine learning, and experimental procedures, we identified and analyzed PD173074, Isoquercitrin, and Rhapontin as potential inhibitors of fibroblast growth factor receptor 3 (FGFR3). Machine learning algorithms guided the initial selection, followed by Quantitative Structure-Activity Relationship (QSAR) modeling and molecular dynamics simulations to evaluate the interaction dynamics and stability of Rhapontin. Physicochemical assessments further verified its drug-like properties and specificity.Results: Our experiments demonstrate that Rhapontin, when combined with Ceritinib, significantly suppresses tumor activity in NSCLC while sparing healthy cells. The molecular simulations and physicochemical evaluations confirm Rhapontin’s stability and favorable interaction with FGFR3, highlighting its potential as an effective adjunct in NSCLC therapy.Discussion: The integration of natural compounds with established cancer therapies offers a promising avenue for enhancing treatment outcomes in NSCLC. By combining the ancient wisdom of natural remedies with the precision of modern science, this study contributes to evolving cancer treatment paradigms, potentially mitigating the side effects associated with current therapies.

show abstract

“…The detection of serum tumor markers is an important method for diagnosing tumors, but specific tumor marker for NSCLC is not available (Park et al, 2022). A growing consensus is that the effective detection of early-stage cancer will likely rely on biomarker panels rather than single biomarkers because of the greater specificity and sensitivity of panels (Król et al, 2023). Therefore, this study aims to discover the new biomarker panels for patients with NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Serum IL‐24 combined with CA125 as screening and prognostic biomarkers for NSCLC

Zhang,

Qu,

Deng

et al. 2024

Cell Biology International

View full text Add to dashboard Cite

Noninvasive and effective methods for early screening of non‐small cell lung cancer (NSCLC) still need to be developed. At present, a reasonable conclusion is that a combination of tumor markers is a superior predictor of screening. Cytokines, as important regulators of cancer development, have great potential for the screening and prognosis of NSCLC. This study screened novel biomarkers related to the early screening and prognosis of NSCLC. In the present study, the biological significance and immunoregulation of interleukin‐24 (IL‐24) were analyzed based on The Cancer Genome Atlas data. Next, 150 serum samples from initially treated patients with NSCLC and 70 controls were collected, and we obtained pathological sections from 60 patients with NSCLC. The ELISA and immunohistochemistry results showed the differential expression of IL‐24 and carbohydrate antigen 125 (CA125). The results show that IL‐24 is an important tumor suppressor in NSCLC that helps to improve the poor prognosis of these patients. A significantly negative correlation between IL‐24 and CA125 levels was also found. Notably, serum IL‐24 levels were significantly negatively correlated with the TNM stage of patients with NSCLC, consistent with an important role for tumor suppressors in NSCLC. The receiver operating characteristic curve analysis showed that a combination of IL‐24 and CA125 was an effective panel for discriminating patients with NSCLC from HD, and individuals with other lung diseases. Serum IL‐24 and CA125 levels were identified as independent prognostic markers for NSCLC. The IL‐24 and CA125 panel exhibited good performance in the screening of NSCLC.

show abstract

Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy—A Review

Cited by 8 publications

References 107 publications

Three-year follow-up study reveals improved survival rate in NSCLC patients underwent guideline-concordant diagnosis and treatment

Three-year follow-up study reveals improved survival rate in NSCLC patients underwent guideline-concordant diagnosis and treatment

Active and machine learning-enhanced discovery of new FGFR3 inhibitor, Rhapontin, through virtual screening of receptor structures and anti-cancer activity assessment

Serum IL‐24 combined with CA125 as screening and prognostic biomarkers for NSCLC

Contact Info

Product

Resources

About